
Thoracic Surgeon @RoswellPark Cancer Center. Cardiothoracic surgery @harvardmed, resident @WCMSurgery, former Surgeon @usairforce, AI researcher and proud Dad
Buffalo, NY
Joined May 2020
- Tweets201
- Following564
- Followers253
- Likes252
Curious about AI/Machine Learning as a Thoracic Surgeon? Check out our review on artificial intelligence applications in thoracic surgery and what the future may hold, out now in @EACTS_Journals. @ammara_a @Laparoscopes @BIDMCSurgery:
academic.oup.com/ejcts/advan…
K. Patrick Seastedt, MD, FACS retweeted
I’m so honored to be featured by the Claude team! What a great surprise to get during clinic AngioView.com
Replying to @claudeai
A cardiology fellow built a 3D tool to help trainees learn to read coronary angiograms.
Just published in Thoracic Surgery Clinics: a review of where AI and machine learning may actually improve risk assessment and complication prediction in thoracic surgery, and what it will take to move these tools into practice.
Free access: authors.elsevier.com/a/1ny3y…
K. Patrick Seastedt, MD, FACS retweeted
K. Patrick Seastedt Shares a Survey About AI Task Force Improvement Regarding Lung Cancer
@SeastedtMD @IASLC
oncodaily.com/technology/k-p…
Please consider completing and sharing this survey to help the AI task force at @IASLC focus our efforts on where AI can help you and your patients with lung cancer the most @ElliotServaisMD @BrendonStilesMD @FordePatrick @ShandaBlackmon @StephenVLiu @LindaMThoracic @ChiFuJeffYang @AATSHQ @STS_CTsurgery @GenThorSurgClub @thoracic @EACTS
K. Patrick Seastedt, MD, FACS retweeted
Our clinical trial of AMIE, a patient-facing AI system, was just published in The Lancet.
I want to explain what *I* think this study ACTUALLY means.
It's about a fundamental question: how do we know that clinical AI works?
🧵⬇️
xitter.cf/Google/status/21083245…
Our medical research system, AMIE, is the first patient-facing conversational diagnostic tool of its kind to be studied prospectively in a real-world clinical setting.
In a study, published today in @TheLancet, we found that when patients chatted with AMIE before an in-person appointment, the interaction built their confidence and helped them organize their thoughts. And physicians who reviewed the information from the patient conversation got more time back to focus on collaborative care and shared decision-making instead of digging through data.
K. Patrick Seastedt, MD, FACS retweeted
In Memoriam: Dominique Vervoort, MD, MPH, MBA (1994-2026) - CJC Open cjcopen.ca/article/S2589-790… 💔🙏
K. Patrick Seastedt, MD, FACS retweeted
Dr. Pat Seastedt (@SeastedtMD) gave a thought-provoking talk at #ITSOS2026 on where AI could change thoracic care: risk-based screening eligibility; NLP to find eligible patients missed by structured EHR data; AI-assisted CT interpretation, which may reduce missed referrals; more consistent preoperative risk assessment; and potentially measurable surgical quality through video analysis and process auditing.
His caution was clear: AI can make care more consistent without making it more equitable. We need to measure who benefits at every step, validate subgroup performance locally before and after deployment, and have thoracic surgeons help lead implementation.
K. Patrick Seastedt, MD, FACS retweeted
Really impressed by this session at #ITSOS2026: “Disparities in Access and Treatment for Personalized Cancer Care.”
Every presentation was thought-provoking & each gave me something practical to take home and act on. Such an amazing line up!!!
Speakers:
Alex Potter, Harvard Medical School (@alexandra_p_24)
Amie Miller, Sarasota Memorial Health)
Fatima Wilder, MGB (@FWilder9)
Alexis Chidi, MSK (@AlexisChidi)
Patrick Seastedt, Roswell Park (@SeastedtMD)
Discussants
Loretta Erhunmwunsee, City of Hope (@LorettaEMD)
John Waters, UT Southwestern)
Moderated by Neel Chudgar, Montefiore (@nchudgar) and Jane Yanagawa, UCLA
K. Patrick Seastedt, MD, FACS retweeted
Memorial Sloan Kettering opening its precision oncology data to physicians nationwide through OpenEvidence. Today's Forbes has the story.
@MSKCancerCenter has spent years building the world's most detailed map of which cancer mutations respond to which treatments. Until now, you had to be treated at MSK to benefit from it. Soon, an oncologist in a small practice in Montana will see the same evidence as a subspecialist in Manhattan, at the moment it matters, for the patient in front of them.
More patients getting the right treatment the first time, wherever they live. Read full article here forbes.com/sites/innovationr…
K. Patrick Seastedt, MD, FACS retweeted
Dr. @MartinReck2 presents MDT-Bridge at #WCLC26: pts with resectable or borderline resectable NSCLC received 1-2 cycles of durvalumab + chemotherapy then surgery if resectable or CRT if not, followed by adjuvant/consolidation durvalumab. Of those with borderline resectable NSCLC, 62% underwent resection (97% R0). Overall resection rate 75% and 27% pCR rate.
K. Patrick Seastedt, MD, FACS retweeted
I agree with Dario that we need to pace the frontier. This has been a primary topic of discussions we've had at OpenAI in recent weeks.
Committing to having independent evaluators with employee-like access is a great idea, and we will do the same. We'll have more to share soon.
We Must Pace the Frontier: I’ve written a new essay on why the AI industry should slow down, with a three-part plan for doing so.
Anthropic is unilaterally committing to the first of these steps. We’ll provide third-party evaluators with permanent, employee-level access to our systems, so that they can verify adherence to our safety measures, report on incidents, and assess models’ alignment during training.
You can read the full post here: darioamodei.com/post/we-must…
K. Patrick Seastedt, MD, FACS retweeted
In this Exploring AI in Oncology episode, @WaqasHaqueMD talks with Kenneth Patrick @SeastedtMD of @RoswellPark about MIRACLE, an #AI platform designed to predict #LungCancer surgery complications and personalize surgical risk assessment.
Watch here! youtu.be/9OMxBiN8ZGI
K. Patrick Seastedt, MD, FACS retweeted
Whether you are a physician or a patient, your opinion matters ! Please help us by filling out this survey about AI in the care of patients with cancer
@IASLC @RETpositive @AlkRos1France @reseauKpoumon @MarceloCorassa @StephenVLiu @PrelajArsela @ElinardouHelena
🔥IASLC #AI Artificial Intelligence Taskforce Survey
🆙 @IASLC #AI Taskforce
☑️Leads: @mihaela_aldea @SeastedtMD Dr. Muhammad Rafiqul Islam
🎯Parallel, mutually complementary surveys for physicians and patients
🎯Addressing global challenges in AI accessibility
▶️Patient: iaslc.co1.qualtrics.com/jfe/…
▶️Physician: iaslc.co1.qualtrics.com/jfe/…
#LCSM @OncoAlert @Larvol @EGFRResisters @ALKPositiveinc @ros1cancer @KRASKickers @Exon20Group @RETRenegades @metcrusaders
*Image Created by @HHorinouchi with Gemini
K. Patrick Seastedt, MD, FACS retweeted
🔥IASLC #AI Artificial Intelligence Taskforce Survey
🆙 @IASLC #AI Taskforce
☑️Leads: @mihaela_aldea @SeastedtMD Dr. Muhammad Rafiqul Islam
🎯Parallel, mutually complementary surveys for physicians and patients
🎯Addressing global challenges in AI accessibility
▶️Patient: iaslc.co1.qualtrics.com/jfe/…
▶️Physician: iaslc.co1.qualtrics.com/jfe/…
#LCSM @OncoAlert @Larvol @EGFRResisters @ALKPositiveinc @ros1cancer @KRASKickers @Exon20Group @RETRenegades @metcrusaders
*Image Created by @HHorinouchi with Gemini
The authors of this perspective cannot be more wrong. 5 reasons why:
1/ It is already well known that when you clearly scope a task to a defined input set, or when the input data is clearly defined with a known prevalence of disease, AI will almost always outperform clinicians. This covers tasks like interpreting free text, differential diagnosis, or prescribing treatment or management. What is much less clear are the grey areas where interpretation is open-ended, especially when there is no clear pathological signal, such as the early onset of a chronic disease. These are usually the areas where AI models underperform and where clinical judgement plays a critical role. For example, how do you integrate a person's history, symptoms and context to decide which additional clinical tests to order and ultimately establish a differential diagnosis?
2/ The perspective heavily cites AI systems such as Google's AMIE as evidence that AI is about to surpass physicians. But note how these systems are evaluated. Much of the evidence comes from simulated clinical encounters or carefully constructed cases, which may contain far less of the noise, ambiguity and incompleteness of real-world clinical care. In such clean and bounded data spaces, it is not particularly surprising that AI performs exceptionally well. The authors themselves acknowledge that most studies comparing AI and physicians are simulations of discrete cognitive medical tasks rather than analyses of real clinical interactions.
3/ More importantly, none of this gives us enough evidence to make such a sweeping conclusion about autonomous AI. Where are the randomized, prospective, real-world trials comparing AI alone vs physicians vs AI + physicians across actual clinical workflows? The perspective cites studies mainly with carefully constructed evaluations and retrospective comparisons, but very little evidence of AI operating across the messiness of real clinical care. And yet from this relatively narrow evidence base, the argument moves quite confidently towards AI-alone care becoming superior to AI-aided physicians.
4/ Somehow I feel the authors have treated medicine like a game where the winner deserves to replace the weaker entity, which in this case happens to be the human. But medicine is not a zero-sum game. Humans have never been particularly good pattern recognizers in very high-dimensional data spaces, and this is not something they should have to do alone in the first place. Their job is to provide care using whatever tools are available at their disposal, from the simplest stethoscope to a frontier LLM. It involves understanding context, uncertainty, preferences, and treating another human being with compassion, empathy and as little bias as possible.
5/ I strongly believe the future is AI + human, not AI vs human, and I think there is even a simple statistical intuition behind this. Independent judgements can cancel out each other's errors. There is a reason aggregated or crowd-sourced judgement can outperform a standalone opinion. So the more interesting question is not whether AI will replace physicians. It is how we can design AI + clinician systems where one compensates for the weaknesses of the other, and together they provide better care than either could alone
Game mostly over for human doctors vs. AI? @ZekeEmanuel @AbeBakerButler @nealkhosla and I just published in @JAMA_current: AI-alone may provide better patient care than physicians or physician-controlled hybrids at 5 fundamental cognitive medical tasks is unsettling but seems probable. Even when AI alone is superior, significant barriers to implementation remain. Nonetheless, superior autonomous AI will likely be ready to be deployed for real-world cognitive medical tasks in some, maybe many, workflows by 2030. Consequently, physicians, policymakers, and others need to urgently devise approaches to workflow, liability, regulation, reimbursement, and medical education.
@DrOz @1klomp time for @CMSGov @CMSinnovates to take note: Will Autonomous AI Exceed AI-Aided Physicians as the Best Medical Care?
jamanetwork.com/journals/jam…
K. Patrick Seastedt, MD, FACS retweeted
Cribbing off Carl Sagan, "in order to answer whether or not an AI system can reason like a physician, we must first ask, what does it mean to reason like a physician?"
K. Patrick Seastedt, MD, FACS retweeted
Congrats to Dr. Chinmay Haridas (@chinmayharidas) on his study evaluating the use of wearables in the US!!
Could wearable data become part of routine surgical care? ⌚️❓🩺
Dr Haridas, @chinmayharidas, explains in this JACS #AuthoroftheMonth feature.
Full study available at: ovid.com/10.1097/XCS.0000000…
@ChiFuJeffYang @alexandra_p_24 @MGHSurgery
K. Patrick Seastedt, MD, FACS retweeted
Replying to @andrewgwils
It's not merely physical agents, it's anything that deals with something else than sequences of discrete symbols.
Any data modality that is high-dimensional, continuous, and possibly noisy is completely out of reach of current generative models.
That includes pretty much all real-world signals (aside from human language, computer languages and mathematics).
Furthermore, you can't have reliable agents unless they have the ability to predict the consequences of their actions and plan accordingly. LLMs simply don't.
K. Patrick Seastedt, MD, FACS retweeted
One of the biggest challenges I see for Claude and AI in biotech drug development is that LLMs are based on published data, patents, etc. But when industry (and my company) try to replicate published work, the failure rate is at least 50-65%. How does the AI know what to trust?




































